Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARCO: Microbiota Augmentation in Liver Disease
NCT06871111Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in liver disease, liver failure and Cirrhosis (9 arms), sponsored by University of Chicago. Primary endpoints: Incidence of adverse events (AEs and SAEs) attributable to the Commensal Consortia and Patient-Reported Outcomes Measurement Information System (PROMIS) scores. Started Aug 2025; status: recruiting.
02
Conditions
liver diseaseliver failureCirrhosis
Beyond the preview
Go deeper on NCT06871111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06871111.